Our drug and target discovery innovation platform creates an accelerated, scalable, end-to-end
process from identification of an unmet need to commercialization that is industry-leading
The complexity of the GBA presents an ideal opportunity to deploy an AI-driven approach to drug and target discovery. At Invea, we use an AI-powered platform, GBAnkTM, to assimilate our data universe of omics, biological (cellular and molecular), pharmacology, clinical, disease (rare and common), symptomatology, real-world evidence, and commercial sources. The platform generates hypotheses for re-innovation or novel programs that our discovery experts prioritize for efficacy, safety, and the highest likelihood of success.